🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% eachUnlock Stocks

4 big analyst picks: Rambus stock surges on Jefferies upgrade

Published 2023-05-19, 06:34 a/m
© Reuters
TEVA
-
RMBS
-
WEC
-
DT
-

Here is your Pro Recap of the biggest analyst picks you may have missed since yesterday: upgrades for Rambus, WEC Energy, Dynatrace, and Teva Pharma.

InvestingPro subscribers got this news before anyone else. Start your 7-day trial to get on board.

Rambus shares soar on Jefferies upgrade

Rambus (NASDAQ:RMBS) shares surged more than 9% yesterday after Jefferies upgraded the company to Buy from Hold and raised its price target to $65.00 from $45.00, as reported in real time on InvestingPro.

The upgrade followed recent meetings with management and increased confidence in the company’s positioning. According to Jefferies, the company is well positioned for not only leading buffer chip share in ramping DDR5 but also for a meaningful share in the significant adjacent growth opportunities of companion chips and CXL.

Earlier this month, the company reported its Q1 earnings, significantly missing the Street estimates.

InvestingPro | Know Market Moves

WEC Energy upgraded to Buy at Mizuho

Mizuho Securities upgraded WEC Energy (NYSE:WEC) to Buy from Neutral with a price target of $98.00.

According to the firm, regulatory concerns that resulted in a stock underperformance over the past two months are overblown given WEC largely resolved its WI filings earlier this year, covering the WI utilities through 2024. Furthermore, on the IL side, the firm noted that the staff testimony published earlier this month appears constructive.

2 more upgrades

BTIG upgraded Dynatrace (NYSE:DT) to Buy from Neutral with a price target of $57.00 following the Q4 beat on Wednesday, highlighted by upside on all key metrics.

According to BTIG, growth appears to be stabilizing despite macro headwinds and ongoing customer cloud optimization initiatives. Furthermore, the firm noted that commentary on new products, namely application security and log monitoring, was encouraging.

Evercore ISI upgraded Teva Pharma (NYSE:TEVA) to Outperform from In Line following the company's reported Q1 results last week, with revenue coming in better than expected, while EPS missing the estimates.

In fast-moving markets, every second counts - and InvestingPro subscribers are always one step ahead with lightning-quick updates.

Start your free 7-day trial now.

InvestingPro | Be The First To Know

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.